General

DEEPCHEK® ASSAY 13-PLEX KB DRUG SUSCEPTIBILITY TESTING IS NOW CE-IVD MARKED

We are pleased to announce that our DeepChek® Assay 13-Plex KB Drug Susceptibility Testing, intended to be used for Tuberculosis Drug Resistance assessment through NGS sequencing, is now CE-IVD marked ! ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574 Email : contact@abldiagnostics.com Email 2 : fauvet-girel@ablsa.com Envelope

DEEPCHEK® ASSAY 13-PLEX KB DRUG SUSCEPTIBILITY TESTING IS NOW CE-IVD MARKED Read More »

Presentation of the DeepChek®-HIV Whole Genome Assay at ECCMID 2022

We are pleased to announce a new poster presentation entitled “Evaluation of a commercial assay whole genome HIV-1 using next-generation sequencing” at ECCMID 2022. Link to the poster presentation. Please feel free to contact us to get more information. ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061

Presentation of the DeepChek®-HIV Whole Genome Assay at ECCMID 2022 Read More »

ÉTABLISSEMENTS FAUVET GIREL – RÉSULTATS ANNUELS 2021

ETABLISSEMENTS FAUVET GIREL (FR0000063034 – FAUV – Euronext Paris) publie ses résultats annuels au titre de l’exercice clos le 31 décembre 2021, arrêtés par le Conseil d’administration du 8 février 2022. Les comptes ont été audités par le commissaire aux comptes dont le rapport de certification est en cours d’émission. Résultats annuels 2021 ETABLISSEMENTS FAUVET

ÉTABLISSEMENTS FAUVET GIREL – RÉSULTATS ANNUELS 2021 Read More »

ABL announce a new Distribution Agreement with Geneplus Co Ltd in Thailand

Advanced Biological Laboratories (ABL) S.A. and Geneplus Co Ltd are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Thailand See all the current Distributors ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone :

ABL announce a new Distribution Agreement with Geneplus Co Ltd in Thailand Read More »

RÉSULTAT DE L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE VISANT LES ACTIONS DE LA SOCIÉTÉ ÉTABLISSEMENTS FAUVET-GIREL, INITIÉE PAR ADVANCED BIOLOGICAL LABORATORIES S.A

L’offre publique d’achat simplifiée visant les actions ETABLISSEMENTS FAUVET-GIREL, initiée le23 décembre 2021 par ADVANCED BIOLOGICAL LABORATORIES SA (« ABL SA »), s’est clôturée le 7 janvier 2022. A l’occasion de cette offre, ABL SA a acquis 954 actions représentant 0,38% du capital et 0,38% des droits de vote de la société ETABLISSEMENTS FAUVET-GIREL. À la clôture de

RÉSULTAT DE L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE VISANT LES ACTIONS DE LA SOCIÉTÉ ÉTABLISSEMENTS FAUVET-GIREL, INITIÉE PAR ADVANCED BIOLOGICAL LABORATORIES S.A Read More »

ABL Announces Distribution Agreement with Hayleys Lifesciences in Sri Lanka

Advanced Biological Laboratories (ABL) S.A. and Hayleys Lifesciences  are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Sri Lanka. See all the current Distributors ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone :

ABL Announces Distribution Agreement with Hayleys Lifesciences in Sri Lanka Read More »

The Luxembourg Institute of Health and Advanced Biological Laboratories develop joint Diagnostic Solutions to measure neutralizing antibodies against Sars CoV-2 variants

The Luxembourg Institute of Health (LIH) and Advanced Biological Laboratories (ABL) are joining forces to predict immune protection against COVID-19 and support long-term vaccination strategies. To this end, the two laboratories have signed a license agreement and a collaboration agreement to provide two in vitro diagnostic solutions to measure neutralizing antibody levels.   LIH has established a

The Luxembourg Institute of Health and Advanced Biological Laboratories develop joint Diagnostic Solutions to measure neutralizing antibodies against Sars CoV-2 variants Read More »

ABL ANNOUNCES DISTRIBUTION AGREEMENT WITH MEDSOL IN SAUDI ARABIA

ABL announces Distribution Agreement with Medsol in Saudi Arabia Advanced Biological Laboratories (ABL) S.A. and Medsol Corporation  are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Saudi Arabia. See current channel partners. Find us on: ABL DIAGNOSTICS   42,

ABL ANNOUNCES DISTRIBUTION AGREEMENT WITH MEDSOL IN SAUDI ARABIA Read More »

Scroll to Top